Your browser doesn't support javascript.
loading
Predicting drug-drug interactions by graph convolutional network with multi-kernel.
Wang, Fei; Lei, Xiujuan; Liao, Bo; Wu, Fang-Xiang.
Afiliação
  • Wang F; Division of Biomedical Engineering, University of Saskatchewan, 57 Campus Drive, S7N 5A9, Saskatchewan, Canada.
  • Lei X; School of Computer Science, Shaanxi Normal University, 620 West Chang'an Avenue, 710119, Shaanxi, China.
  • Liao B; School of Mathematics and Statistics, Hainan Normal University, 99 Longkun South Road, 571158, Hainan, China.
  • Wu FX; Division of Biomedical Engineering, University of Saskatchewan, 57 Campus Drive, S7N 5A9, Saskatchewan, Canada.
Brief Bioinform ; 23(1)2022 01 17.
Article em En | MEDLINE | ID: mdl-34864856
Drug repositioning is proposed to find novel usages for existing drugs. Among many types of drug repositioning approaches, predicting drug-drug interactions (DDIs) helps explore the pharmacological functions of drugs and achieves potential drugs for novel treatments. A number of models have been applied to predict DDIs. The DDI network, which is constructed from the known DDIs, is a common part in many of the existing methods. However, the functions of DDIs are different, and thus integrating them in a single DDI graph may overlook some useful information. We propose a graph convolutional network with multi-kernel (GCNMK) to predict potential DDIs. GCNMK adopts two DDI graph kernels for the graph convolutional layers, namely, increased DDI graph consisting of 'increase'-related DDIs and decreased DDI graph consisting of 'decrease'-related DDIs. The learned drug features are fed into a block with three fully connected layers for the DDI prediction. We compare various types of drug features, whereas the target feature of drugs outperforms all other types of features and their concatenated features. In comparison with three different DDI prediction methods, our proposed GCNMK achieves the best performance in terms of area under receiver operating characteristic curve and area under precision-recall curve. In case studies, we identify the top 20 potential DDIs from all unknown DDIs, and the top 10 potential DDIs from the unknown DDIs among breast, colorectal and lung neoplasms-related drugs. Most of them have evidence to support the existence of their interactions. fangxiang.wu@usask.ca.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Algoritmos / Reposicionamento de Medicamentos Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Algoritmos / Reposicionamento de Medicamentos Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article